Aquamid represents a new generation of soft-tissue fillers thanks to the lack of particles and a very high concentration of water. Aquamid is the result of a new, patented production method called "In line Cross-Linking Technology" (ILX Technology). The Aquamid gel contains 2.5% polyacrylamide (PAAG) and 97.5% water. It is homogenous, perfectly stable and nonbiodegradable and has optimum viscosity and elasticity. Aquamid has been authorized for sale in Europe since March 2001 as a new medical device (CE-mark 0543). This pilot study presents our experiences with Aquamid based on 59 subjects treated with 77 doses mainly used for aesthetic correction but even on medical indication. Lip augmentation was the most frequent procedure (72%), dominated by the age groups from 20 to 25 and from 50 to 60 years. Cheekbone enlargement was carried out in 13% of the cases. The rest concerned augmentation of deep naso-labial fold, glabella, and chin with 5% representation of each. The patient satisfaction was almost 100% with the aesthetic results and either short time or long time side effect reported during a follow-up period of 9 months (range: 2 to 16 months). Aquamid is easy to use without any pretest. Considering its long-lasting effect and the need for sterile conditions with use, only qualified and experienced staff, preferably physicians, should administrate the gel. Adequate indication, correct handling, and thoughtful following of the recommendations/cautions are of vital importance. Given that, aquamid seems to be a promising long-lasting soft tissue filler.